D3/Penta 21 clinical trial design: A randomised non-inferiority trial with nested drug licensing substudy to assess dolutegravir and lamivudine fixed dose formulations for the maintenance of virological suppression in children with HIV-1 infection, aged 2 to 15 years-Reference-Cited by-同舟云学术

D3/Penta 21 clinical trial design: A randomised non-inferiority trial with nested drug licensing substudy to assess dolutegravir and lamivudine fixed dose formulations for the maintenance of virological suppression in children with HIV-1 infection, aged 2 to 15 years

Published:2024-07 Issue: Volume:142 Page:107540
ISSN:1551-7144
Container-title:Contemporary Clinical Trials
language:en
Short-container-title:Contemporary Clinical Trials

Author:

Turkova Anna,Chan Man K.,Kityo Cissy,Kekitiinwa Adeodata R.,Musoke Philippa,Violari Avy,Variava Ebrahim,Archary Moherndran,Cressey Tim R.,Chalermpantmetagul Suwalai,Sawasdichai Kanokkorn,Ounchanum Pradthana,Kanjanavanit Suparat,Srirojana Sakulrat,Srirompotong Ussanee,Welch Steven,Bamford Alasdair,Epalza Cristina,Fortuny Clàudia,Colbers Angela,Nastouli Eleni,Walker Simon,Carr Dan,Conway Magda,Spyer Moira J.,Parkar Nazia,White Iona,Nardone Alessandra,Thomason Margaret J.,Ferrand Rashida A.,Giaquinto Carlo,Ford Deborah

Publisher

Elsevier BV

Reference50 articles.

1. Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: a planned 24 week analysis of the DOLAM randomized clinical trial;Blanco;J. Antimicrob. Chemother.,2018

2. SOLAR 3D: A prospective study switching to DTG/3TC from 3-or 4-drug ART for maintenance of viral suppression with historic M184V/I mutation and prior virological failures: 48 week primary endpoint results;Blick,2021

3. Long-term evaluation of residual viremia in a clinical trial of dolutegravir plus lamivudine as maintenance treatment for participants with and without prior lamivudine resistance;De Miguel Buckley;Open Forum Infect. Dis.,2022

4. Dolutegravir and lamivudine maintenance therapy in HIV-1 virologically suppressed patients: results of the ANRS 167 trial (LAMIDOL);Joly;J. Antimicrob. Chemother.,2019

5. No significant changes to residual viremia after switch to dolutegravir and lamivudine in a randomized trial;Li;Open Forum Infect. Dis.,2019

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Paediatric antiretroviral therapy challenges with emerging integrase resistance;Current Opinion in HIV and AIDS;2024-07-05